Brexit Could Rob Industry Of Access To Markets Covered By 35 EU Free Trade Deals
Executive Summary
A coalition of life sciences industry bodies has written a position paper outlining its concerns about Brexit in areas such as EU free trade deals, customs declarations and tariff barriers.
You may also be interested in...
Pharma Execs Flag Up More Brexit Regulatory Woes – And A Possible Solution
Pharma executives painted a rather bleak picture of a UK regulatory system cast adrift by a hard Brexit, with problems likely in areas such as drug approvals, clinical trials and the role of the MHRA. One solution was proposed, however, to avoid the need for a free-standing UK approvals system for new drugs.
Post-Brexit UK Risks Being ‘Left Out In The Cold’ As EU Coordinates Action On Shortages
The UK is not alone in experiencing drug shortages, as data from across Europe show, but its departure from the EU makes it more difficult to respond to supply chain pressures, according to new research.
EU Countries Offered Funding To Contribute to African Regulatory Strengthening
Training projects are intended to strengthen the African regulatory environment, boost the capacity of the African Medicines Agency, facilitate regulatory reliance, and increase joint new drug assessments.